Interleukin 12 : antitumor activity and immunotherapeutic potential in oncology /
Saved in:
| Author / Creator: | Lasek, Witold, author. |
|---|---|
| Imprint: | Cham, Switzerland : Springer, ©2016. |
| Description: | 1 online resource |
| Language: | English |
| Series: | SpringerBriefs in immunology, 2194-2773 SpringerBriefs in immunology. |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11267249 |
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | 11267249 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 161005s2016 sz o 000 0 eng d | ||
| 005 | 20240513212456.5 | ||
| 019 | |a 960030609 |a 960088116 |a 961877593 |a 962051520 |a 962691475 |a 964543584 |a 964843525 |a 964928733 |a 965734520 |a 967614749 |a 981088397 |a 988804901 |a 1005769966 |a 1012067291 |a 1048181659 |a 1066474174 |a 1112573757 |a 1112975578 |a 1113385750 |a 1117079303 |a 1122819383 |a 1159614364 | ||
| 020 | |a 9783319469065 |q (electronic bk.) | ||
| 020 | |a 3319469061 |q (electronic bk.) | ||
| 020 | |z 9783319469058 | ||
| 020 | |z 3319469053 | ||
| 024 | 7 | |a 10.1007/978-3-319-46906-5 |2 doi | |
| 035 | |a (OCoLC)959952988 |z (OCoLC)960030609 |z (OCoLC)960088116 |z (OCoLC)961877593 |z (OCoLC)962051520 |z (OCoLC)962691475 |z (OCoLC)964543584 |z (OCoLC)964843525 |z (OCoLC)964928733 |z (OCoLC)965734520 |z (OCoLC)967614749 |z (OCoLC)981088397 |z (OCoLC)988804901 |z (OCoLC)1005769966 |z (OCoLC)1012067291 |z (OCoLC)1048181659 |z (OCoLC)1066474174 |z (OCoLC)1112573757 |z (OCoLC)1112975578 |z (OCoLC)1113385750 |z (OCoLC)1117079303 |z (OCoLC)1122819383 |z (OCoLC)1159614364 | ||
| 035 | 9 | |a (OCLCCM-CC)959952988 | |
| 037 | |n Title purchased via APUC SHEDL / ScopNet ebook agreement |n Biomedical and Life Sciences (Springer-11642) | ||
| 040 | |a YDX |b eng |e pn |c YDX |d GW5XE |d NJR |d EBLCP |d IDEBK |d UPM |d STF |d OCLCF |d COO |d OCLCO |d OCLCQ |d OCLCO |d OCLCA |d MERER |d OCLCO |d IDB |d JG0 |d OCLCO |d OCLCQ |d OCLCO |d IOG |d OCLCQ |d OCLCO |d IAD |d JBG |d VT2 |d ICW |d OCLCO |d UAB |d OCLCO |d ILO |d OCLCO |d ICN |d OCLCO |d OCLCQ |d ESU |d N$T |d OCLCO |d U3W |d MERUC |d OCLCO |d REB |d OCLCO |d CAUOI |d OCLCO |d OCLCQ |d OCLCO |d KSU |d INT |d AU@ |d OCLCO |d WYU |d OCLCQ |d OCLCO |d OCLCA |d OCLCQ |d OCLCO |d UKAHL |d OCLCQ |d ERF |d UKBTH |d ADU |d LEATE |d OCLCQ |d OCLCA |d OCLCQ | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a QR185.8.I56 | |
| 060 | 4 | |a QW 568 | |
| 072 | 7 | |a MJCM |2 bicssc | |
| 072 | 7 | |a MED044000 |2 bisacsh | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 100 | 1 | |a Lasek, Witold, |e author. | |
| 245 | 1 | 0 | |a Interleukin 12 : |b antitumor activity and immunotherapeutic potential in oncology / |c Witold Lasek, Radoslaw Zagozdzon ; with a contribution by Marek Jakóbisiak. |
| 260 | |a Cham, Switzerland : |b Springer, |c ©2016. | ||
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file | ||
| 347 | |b PDF | ||
| 490 | 1 | |a SpringerBriefs in immunology, |x 2194-2773 | |
| 588 | 0 | |a Print version record. | |
| 520 | |a This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). | ||
| 505 | 0 | 0 | |g Machine generated contents note: |g 1. |t Biology of IL-12 / |r Witold Lasek -- |g 2. |t Antitumor Effects of IL-12 in Preclinical Studies / |r Marek Jakobisiak. |
| 650 | 0 | |a Interleukin-12. |0 http://id.loc.gov/authorities/subjects/sh96009262 | |
| 650 | 2 | |a Interleukins. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Interleukin-12. |2 fast |0 (OCoLC)fst00976421 | |
| 655 | 4 | |a Electronic books. | |
| 700 | 1 | |a Zagozdzon, Radoslaw, |e author. | |
| 700 | 1 | |a Jakóbisiak, Marek. | |
| 776 | 0 | 8 | |i Print version: |a Lasek, Witold. |t Interleukin 12. |d Cham, Switzerland : Springer, ©2016 |z 9783319469058 |z 3319469053 |w (OCoLC)957509038 |
| 830 | 0 | |a SpringerBriefs in immunology. |0 http://id.loc.gov/authorities/names/no2013144282 | |
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i d8c0419f-c13d-52cc-931c-9ef271fd467e |s c7d4d13b-b9df-563a-8f78-bc5c4e9ba307 |
| 928 | |t Library of Congress classification |a QR185.8.I56 |l Online |c UC-FullText |u https://link.springer.com/10.1007/978-3-319-46906-5 |z Springer Nature |g ebooks |i 12540787 | ||